Back
 AJAC  Vol.1 No.1 , May 2010
Validation of HPLC and FIA Spectrophotometric Methods for the Determination of Lansoprazole in Pharmaceutical Dosage Forms and Human Plasma
Idrees F. Al-Momani, Majdoleen H. Rababah
Abstract: A chromatographic and aspectrophotometric methods for the quantitative determination of lansoprazole in pharmaceutical combinations and human plasma were developed. The analytical parameters were studied according to International Conference on Harmonization guidelines. The Flow Injection Analysis (FIA) method is based on the oxidation of lansoprazole by a known excess of N-bromosuccinimide (NBS) in an acidic medium, followed by a reaction of excess oxidant with chloranilic acid (CAA) to bleach its purple color. The separation was carried out using RP-C18 column with a mobile phase composed of ACN: TEA: phosphate buffer (60: 0.2: 39.8 v/v) adjusted to pH = 4.
Keywords: Lansoprazole, FIA, HPLC, Pharmaceutical Products, Human Plasma
Cite this paper: I. Al-Momani and M. Rababah, "Validation of HPLC and FIA Spectrophotometric Methods for the Determination of Lansoprazole in Pharmaceutical Dosage Forms and Human Plasma," American Journal of Analytical Chemistry, Vol. 1 No. 1, 2010, pp. 34-39. doi: 10.4236/ajac.2010.11005.
References

[1]   J. M. Ritter, L. D. Lewis and T. G. K. Mant, “A Textbook of Clinical Pharmacology,” 4th Edition, Arnold Ltd., London, 1999.

[2]   “The United States Pharmacopoeia,” 27th Edition, “Na-tional Formulary 22,” Asian Edition, Rockville, 2004.

[3]   T. Uno, N. Yasui-Furukori, T. Takahata, K. Sugawara and T. Tateishi, “Determination of Lansoprazole and Two of its Metabolites by Liquid-Liquid Extraction and Automated Column Switching High-Performance—Liquid Chromatography: Application to Measuring CYP2C19 Activity,” Journal of Chromatography B, Vol. 816, No. 1-2, February 2005, pp. 309-314.

[4]   H. Katsuki, A. Hamada, C. Nakamura, K. Arimori and M. Nakano, “High-Performance Liquid Chromatographic Assay for the Simultaneous Determination of Lansopra-zole Enantiomers and Metabolites in Human Liver Mi-crosomes,” Journal of Chromatography B, Vol. 757, No. 1, pp. 127-133.

[5]   Z. A. El-Sheref, A. O. Mohamad, M. G. El-Baradicy and M. F. El-Tarras, “Reversed-Phase High Performance Liquid Chromatographic Method for the Determination of Lansoprazole, Omeprazole and Pantoprazole Sodium Sesquihydrate in Presence of Their Acid-Induced Degra-dation Products,” Chemical and Pharmaceutical Bulletin, Vol. 54, No. 6, June 2006, pp. 814-818.

[6]   M. Miura, H. Tada and T. Suzuki, “Simultaneous Deter-mination of Lansoprazole Enantiomers and their Metabo-lites in Plasma by Liquid Chromatography with Sol-id-Phase Extraction,” Journal of Chromatography B, Vol. 804, No. 2, May 2004, pp. 389-395.

[7]   A. Avgerinos, T. Karidas, C. Potsides and S. Axarlis, “Determination of Lansoprazole in Biological Fluids and Pharmaceutical Dosage by HPLC,” European Journal of Drug Metabolism and Pharmacokinetics, Vol. 23, No. 2, 1998, pp. 329-332.

[8]   M. F. Tutunji, A. M. Qaisi, B. El-Eswed, L. F. Tutunji, “An in Vitro Investigation on Acid Catalyzed Reactions of Proton Pump Inhibitors in the Absence of an Electrophile, International Journal of Pharmaceutics, Vol. 323, No. 1-2, October 2006, pp. 110-116.

[9]   A. Radi, “Adsorptive Stripping Square-Wave Voltamme-tric Study of the Degradation of Lansoprazole in Aqueous Solutions, Microchemical Journal, Vol. 73, No. 3, De-cember 2002, pp. 349-354.

[10]   C. Yardimci and N. Ozaltin, “Electrochemical Studies and Differential Pulse Polarographic Analysis of Lansoprazole in Pharmaceuticals,” The Analyst, Vol. 126, No. 3, March 2001, pp. 361-366.

[11]   N. Rahman, Z. Bano, S. N. Azmi, M. Kashif, “A Kinetic Spectrophotometric Method for the Determination of Lansoprazole in Pharmaceutical Formulations,” Journal of the Serbian Chemical Society, Vol. 71, No. 10, 2006, pp. 1107-1120.

[12]   D. Yeniceli, D. Dogrukol-Ak and M. Tuncel, “Determi-nation of Lansoprazole in Pharmaceuticals Capsules by Flow Injection Analysis Using UV-Detection,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 36, No. 1, September 2004, pp. 145-148.

[13]   N. Ozaltin, “Determination of Lansoprazole in Pharma-ceutical Dosage Forms by Two Different Spectroscopic Methods,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 20, No. 3, July 1999, pp. 599-606.

[14]   “Validation of Analytical Procedures: Methodology,” Proceedings of the International Conference on Harmo-nisation of Technical Requirements of Registration of Pharmaceuticals for Human Use, Geneva, 1996.

 
 
Top